Hillsdale Investment Management Inc. Biocryst Pharmaceuticals Inc Transaction History
Hillsdale Investment Management Inc.
- $1.21 Billion
- Q3 2024
A detailed history of Hillsdale Investment Management Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 830 shares of BCRX stock, worth $7,146. This represents 0.0% of its overall portfolio holdings.
Number of Shares
830Holding current value
$7,146% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding BCRX
# of Institutions
284Shares Held
171MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$175 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$172 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$102 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$78.2 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$76.2 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.6B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...